http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115025091-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 |
| filingDate | 2022-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-115025091-B |
| titleOfInvention | The use of liensinine in the preparation of anti-African swine fever virus drugs |
| abstract | The invention provides the use of liensinine in the preparation of anti-African swine fever virus drugs, belonging to the field of anti-virus applications. It has been proved by experiments that Niensinine exhibits significant antiviral activity in in vitro experiments, and can exhibit strong anti-ASFV infection at a concentration of 5 μM. Liensinine is a natural product extracted from the traditional Chinese medicine lotus seed. It has the functions of lowering blood pressure and inhibiting smooth muscle contraction. Compared with hormones, antibiotics, chemical synthetic drugs, etc., it has no toxic and side effects such as obvious damage to the body's physiological functions. Therefore, Niensinine has a good prospect in the preparation of anti-ASFV drugs. |
| priorityDate | 2022-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.